RxDoctor Payments Data

Roger Nicosia, DO

Family Medicine · Stuart, FLNPI 1548213697

Payments from drug & device makers

$3,440in general payments, 2019–2025

Across 186 payments — averaging $18.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$759
  • AstraZeneca$544
  • AbbVie$530
  • Lilly USA, LLC$360
  • Pfizer$181
  • Amgen$104
  • plus $963 from 25 others

What the payments were for

  • Food & beverage$3,440100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,440 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$47,134
Medicare patients
239
Services billed
482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban30$39,820
OzempicSemaglutide32$34,453
XareltoRivaroxaban16$13,062
FarxigaDapagliflozin Propanediol14$11,898
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$10,826
SymbicortBudesonide/Formoterol Fumarate12$2,897
Rosuvastatin Calcium141$1,997
Atorvastatin Calcium139$1,634
Ventolin HfaAlbuterol Sulfate25$1,344
Potassium Chloride40$1,117
Levothyroxine Sodium82$892
Metoprolol Succinate54$775
Gabapentin47$768
Celecoxib39$730
Albuterol Sulfate HfaAlbuterol Sulfate20$688

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$181$39,82030 claims
Novo NordiskOzempic$759$34,45332 claims
AstraZenecaFarxiga, Symbicort$544$14,79426 claims
Johnson & JohnsonXarelto$19$13,06216 claims
GSKTrelegy Ellipta$98$10,82613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Stuart

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →